GlassScriptPhysician profile
Justin Platzer
NPI 1487834693
$13,468.36
in general payments reported to CMS, 2019-2025
38 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,916 · 2020: $1,468 · 2021: $1,660 · 2022: $2,398 · 2023: $1,925 · 2024: $1,918 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,823 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.09 |
| Education | $203.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,506.70 | 2019-2025 | |
| Janssen Biotech, INC. | $1,516.64 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $1,486.49 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $946.10 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $737.77 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Genzyme Corporation | $682.95 | 2019-2025 | |
| Incyte Corporation | $609.77 | 2021-2025 | Opzelura |
| Ucb, INC. | $573.73 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $537.42 | 2019-2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $500.86 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $401.91 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Vyne Pharmaceuticals INC. | $365.10 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $354.40 | 2022-2025 | Sotyktu |
| Pfizer INC. | $317.34 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.95 | 2019-2023 | Jublia, Arazlo, Duobrii |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $260.45 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $246.63 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $194.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.68 | 2023-2025 | Spevigo |
| Almirall LLC | $107.60 | 2019-2025 | Seysara |
| Celgene Corporation | $90.48 | 2019 | |
| Allergan, INC. | $71.34 | 2019-2022 | |
| Organon LLC | $67.31 | 2025 | Vtama |
| Biofrontera INC. | $57.87 | 2021-2025 | Ameluz |
| Arcutis Biotherapeutics, INC. | $53.44 | 2023-2025 | Zoryve |
| Musculoskeletal Transplant Foundation INC. | $44.30 | 2022 | |
| Mylan Pharmaceuticals INC. | $38.54 | 2019 | |
| Encore Dermatology INC. | $35.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.86 | 2020 | |
| Organogenesis INC. | $31.08 | 2019-2020 | |
| Smith+Nephew, INC. | $28.68 | 2023 | Grafix Pl |
| Acera Surgical, INC. | $23.64 | 2022 | |
| Fresenius Kabi USA, LLC | $21.24 | 2024 | Idacio |
| Sandoz INC. | $18.97 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.39 | 2019 | |
| Triad Life Sciences INC. | $14.28 | 2022 | |
| Next Science LLC | $12.31 | 2019 | |
| Genentech USA, INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Platzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.